In September, technology stocks led the S&P 500's best performers, with 13 of the top 20 winners coming from the sector. Everpure topped the list with a 40.7% gain, followed by Moderna, Intel, and Bloom Energy, each rising over 30%. On the downside, Fair Isaac saw a steep decline of 48.36%, and Gen Digital dropped nearly 29%. This highlights the strong tech sector momentum amid broader market volatility.
September's tech sector surge is still visible in early October trading. On Pluang as of Oct 03, 2026 11:41 WIB, Moderna (MRNA) trades at USD 190.01, up 0.57% for the day, while Intel (INTC) is slightly down 0.56% at USD 119.33. Bloom Energy (BE) shows stronger momentum with a 4.17% gain, priced at USD 289.15, reflecting ongoing interest in these leading tech and industrial stocks.
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
